NeuroMab™ Anti-EGFR BBB Shuttle Antibody(NRZP-1022-ZP3835)

Figure 1 shows that human anti-EGF-r antibodies block the binding of EGF to human epidermoid carcinoma A431 cells in vitro, where (□) describes the results obtained by anti-EGF-r antibodies, and (●) describes the results obtained by mouse monoclonal antibodies 225, and (▴) describe the results obtained with a control, nonspecific, human IgG2 antibody.

Figure 2 shows that human anti-EGF-r antibodies inhibit the binding of EGF to human epidermoid carcinoma A431 cells in vitro, wherein (□) depicts the results achieved by mouse monoclonal antibody 225, and (○) depicts the results achieved by mouse monoclonal antibodies Results 528, (▾) depict the results obtained with the E1.1 antibody and (▴) depict the results obtained with the E2.4 antibody.

Figure 3 shows that human anti-EGF-r antibodies inhibit the binding of TGF-α to human epidermoid carcinoma A431 cells in vitro, where (□) depicts the results obtained with mouse monoclonal antibody 225, and (♦) depicts the results obtained using E6 Results for the2 antibody, (●) depicts the results obtained with the E6.3 antibody (▴) depicts the results obtained with the E7.2 antibody.

Figure 4 shows that human anti-EGF-r antibodies inhibit the binding of EGF to human colon cancer SW948 cells in vitro, where (○) describes the results achieved by anti-EGF-r antibodies, (□) describes the results achieved by mouse monoclonal antibody 225, and (▴) depict results obtained with a control, nonspecific, human IgG2 antibody.

Figure 5 shows that the human anti-EGF-r antibody derived from the XenoMouse II strain inhibits the growth of SW948 cells in vitro, wherein (●) describes the results obtained by the anti-EGF-r antibody, (□) describes the results obtained by the mouse monoclonal antibody 225, and (▴) depict results obtained with a control, nonspecific, human IgG2 antibody.

Figure 6 shows the in vivo inhibition of growth of human epidermoid carcinoma A431 cells in nude mice by using human anti-EGF-r antibody.

In the figure, (▴) depicts the results obtained with 1 mg dose of human anti-EGF-r antibody according to the present invention, and (▾) depicts the results obtained with 0.2 mg dose of human anti-EGF-r antibody. - EGF-r antibodies, (□) depicts the results obtained with a control, non-specific human IgG2 antibody, and (◯) depicts the results obtained using phosphate buffered saline as control.

Figure 7 shows data related to inhibition of epidermoid carcinogenesis in nude mice by using human anti-EGF-r antibody in vivo, showing tumor incidence at day 19.

Figure 8 shows data related to inhibition of epidermoid carcinogenesis in nude mice by using human anti-EGF-r antibody in vivo, showing tumor incidence at day 120.

Figure 9 shows data related to eradication of established human epidermoid tumors in nude mice by in vivo use of human anti-EGF-r antibodies.

In the figure, (Δ) depicts the results obtained with multiple doses of 1 mg of human anti-EGF-r antibody according to the present invention (E7.6.3), and (x) depicts the results obtained with two doses of human anti-EGF-r antibody The results for 125 μg each of doxorubicin, (*) depict the combination of multiple doses of 1 mg each and two doses of 125 μg each of the human anti-EGF-r antibody (E7.6.3) Results obtained for doxorubicin, (▪) depict the results obtained with a control, non-specific, human IgG2 antibody, and (♦) depict the results obtained using phosphate-buffered saline as a control.

Figure 10 shows data related to eradication of established human epidermoid tumors in nude mice by in vivo use of human anti-EGF-r antibodies.

In the figure, (♦) depicts the results obtained with multiple doses of 0.5 mg of human anti-EGF-r antibody (E2.5), (●) depicts two doses of human anti-EGF-r antibody obtained results. 125 μg each of doxorubicin, (Δ) depicts multiple doses of each 0.5 mg human anti-EGF-r antibody with two doses of each 125 μg doxorubicin according to the invention (E2.5), (x ) depicts the results obtained using phosphate-buffered saline as a control, (*) depicts the results obtained using a 1 mg dose of a nonspecific human IgG2 control antibody.

Figure 11 is a Western blot showing preliminary results obtained comparing the inhibitory effects of E7.6.3 and 225 antibodies on EGF-induced tyrosine phosphorylation and EGFr degradation in cultured A431 cells.

Figure 12 is a Western blot showing preliminary results obtained comparing the inhibitory effects of E7.6.3 and 225 antibodies on EGF-induced tyrosine phosphorylation and EGFr degradation in cultured A431 cells.

Figure 13 is a Western blot showing the inhibitory effect of E7.6.3 antibody on EGF-induced tyrosine phosphorylation and EGFr degradation in cultured A431 cells.